Access Reports New MuGard Commericial Strategy In North America

Access is evaluating strategic options for the commercialization of MuGard in North America. MuGard is an FDA approved treatment for oral mucositis.

In connection with the North American rights to MuGard, the previously announced licensing agreement between Access and Milestone Biosciences has been terminated.

Frank Jacobucci, consultant at Access, said: “I have always known the substantial potential for MuGard in the prevention and treatment of oral mucositis as well as it being very important for the medical community, and an exciting commercial opportunity in the pharma sector.”

“I look forward to working with the Access team while preparing for a MuGard launch in North America and bringing additional pharma resources to bear as needed. These efforts will not only maximize the potential for MuGard but, more importantly, provide access and availability for patients; thus improving outcomes I continue to believe that MuGard is a very important product for the cancer community, as the negative impact of oral mucositis on patient health and treatment is very significant,” he added.